ProCE Banner Activity

CE / CME

Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape

Video

On-demand webcast of expert faculty presntation and case discussion on implementing targeted thearpies for patients with advanced biliary tract cancer, including strategies for molecular testing to inform treatment planning.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

Released: June 17, 2024

Expiration: June 16, 2025

Share

Faculty

Mitesh J. Borad

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

James J. Harding

James J. Harding, MD

Gastrointestinal Oncology Service
Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This program is intended for physicians and health care professionals who treat patients with biliary tract cancer who are candidates for targeted systemic therapy.

Program Learning Goal

The goal of this program is to improve learners’ knowledge, confidence, and competence to manage biliary tract cancer in patients who are candidates for targeted systemic therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the known genomic alterations in BTC and their impact on disease progression

  • Plan guideline-concordant molecular testing for individual patients with BTC and suspected genomic alterations

  • Choose an appropriate targeted therapy for patients with unresectable/refractory/metastatic BTC based on the results of molecular testing for genomic alterations

  • Educate patients and caregivers about potential enrollment on clinical trials in the case of alterations without an approved or off-label treatment option

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Mitesh J. Borad, MD: consultant/advisor/speaker: Merck, Servier; researcher: Relay.

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Lipika Goyal, MD, MPhil: researcher: Alyssum Therapeutics, Boehringer Ingelheim, Genentech; consultant: AbbVie, Agenus, Boehringer Ingelheim, Compass Therapeutics, Exelixis, Kinnate Biopharma, Merck, Relay Therapeutics, Servier, Surface Oncology, Taiho, TransThera Biosciences, Tyra Biosciences; data and safety monitoring board: AstraZeneca.

James J. Harding, MD

Gastrointestinal Oncology Service
Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

James J. Harding, MD: researcher: AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Kinnate Biopharma, Loxo@Lilly, Novartis, Polaris, Pfizer, Tvardi, Zymeworks, Yiviva; consultant: Adaptimmune, AstraZeneca, Bristol Myers Squibb, Eisai, Elevar, Exelixis, Hepion, Imvax, Merck (DSMB), Medivir, QED, RayzeBio, Servier, Tempus, Tyra.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 17, 2024, through June 16, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which included participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.